Literature DB >> 19012493

Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer.

Sophia S Wang1, M Concepcion Bratti, Ana Cecilia Rodríguez, Rolando Herrero, Robert D Burk, Carolina Porras, Paula González, Mark E Sherman, Sholom Wacholder, Z Elizabeth Lan, Mark Schiffman, Stephen J Chanock, Allan Hildesheim.   

Abstract

BACKGROUND: We examined host genetic factors to identify those more common in individuals whose human papillomavirus (HPV) infections were most likely to persist and progress to cervical intraepithelial neoplasia grade 3 (CIN3) and cancer.
METHODS: We genotyped 92 single-nucleotide polymorphisms (SNPs) from 49 candidate immune response and DNA repair genes obtained from 469 women with CIN3 or cancer, 390 women with persistent HPV infections (median duration, 25 months), and 452 random control subjects from the 10,049-woman Guanacaste Costa Rica Natural History Study. We calculated odds ratios and 95% confidence intervals (CIs) for the association of SNP and haplotypes in women with CIN3 or cancer and HPV persistence, compared with random control subjects.
RESULTS: A SNP in the Fanconi anemia complementation group A gene (FANCA) (G501S) was associated with increased risk of CIN3 or cancer. The AG and GG genotypes had a 1.3-fold (95% CI, 0.95-1.8-fold) and 1.7-fold (95% CI, 1.1-2.6-fold) increased risk for CIN3 or cancer, respectively (P(trend) = .008; referent, AA). The FANCA haplotype that included G501S also conferred increased risk of CIN3 or cancer, as did a different haplotype that included 2 other FANCA SNPs (G809A and T266A). A SNP in the innate immune gene IRF3 (S427T) was associated with increased risk for HPV persistence (P(trend) = .009).
CONCLUSIONS: Our results require replication but support the role of FANCA variants in cervical cancer susceptibility and of IRF3 in HPV persistence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19012493      PMCID: PMC3690375          DOI: 10.1086/595563

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  37 in total

1.  Score tests for association between traits and haplotypes when linkage phase is ambiguous.

Authors:  Daniel J Schaid; Charles M Rowland; David E Tines; Robert M Jacobson; Gregory A Poland
Journal:  Am J Hum Genet       Date:  2001-12-27       Impact factor: 11.025

Review 2.  Host and viral genetics and risk of cervical cancer: a review.

Authors:  Allan Hildesheim; Sophia S Wang
Journal:  Virus Res       Date:  2002-11       Impact factor: 3.303

Review 3.  Polymorphisms in DNA repair genes and associations with cancer risk.

Authors:  Ellen L Goode; Cornelia M Ulrich; John D Potter
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-12       Impact factor: 4.254

4.  HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica.

Authors:  M Schiffman; R Herrero; A Hildesheim; M E Sherman; M Bratti; S Wacholder; M Alfaro; M Hutchinson; J Morales; M D Greenberg; A T Lorincz
Journal:  JAMA       Date:  2000-01-05       Impact factor: 56.272

5.  Cancer of the uterine cervix may be significantly associated with a gene polymorphism coding for increased IL-10 production.

Authors:  G A Stanczuk; E N Sibanda; C Perrey; M Chirara; V Pravica; I V Hutchinson; S A Tswana
Journal:  Int J Cancer       Date:  2001-12-15       Impact factor: 7.396

6.  Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica.

Authors:  R Herrero; A Hildesheim; C Bratti; M E Sherman; M Hutchinson; J Morales; I Balmaceda; M D Greenberg; M Alfaro; R D Burk; S Wacholder; M Plummer; M Schiffman
Journal:  J Natl Cancer Inst       Date:  2000-03-15       Impact factor: 13.506

7.  Heritability of cervical tumours.

Authors:  P K Magnusson; P Lichtenstein; U B Gyllensten
Journal:  Int J Cancer       Date:  2000-12-01       Impact factor: 7.396

8.  Polymorphism in codons 10 and 25 of the transforming growth factor-beta 1 (TGF-beta1) gene in patients with invasive squamous cell carcinoma of the uterine cervix.

Authors:  G A Stanczuk; S A Tswana; S Bergstrom; E N Sibanda
Journal:  Eur J Immunogenet       Date:  2002-10

Review 9.  The Fanconi anaemia/BRCA pathway.

Authors:  Alan D D'Andrea; Markus Grompe
Journal:  Nat Rev Cancer       Date:  2003-01       Impact factor: 60.716

Review 10.  Chapter 5: Viral and host factors in human papillomavirus persistence and progression.

Authors:  Sophia S Wang; Allan Hildesheim
Journal:  J Natl Cancer Inst Monogr       Date:  2003
View more
  56 in total

Review 1.  Genomic instability and cancer: lessons learned from human papillomaviruses.

Authors:  Nina Korzeniewski; Nicole Spardy; Anette Duensing; Stefan Duensing
Journal:  Cancer Lett       Date:  2010-11-13       Impact factor: 8.679

2.  Chlamydia trachomatis and risk of prevalent and incident cervical premalignancy in a population-based cohort.

Authors:  Mahboobeh Safaeian; Koen Quint; Mark Schiffman; Ana Cecilia Rodriguez; Sholom Wacholder; Rolando Herrero; Allan Hildesheim; Raphael P Viscidi; Wim Quint; Robert D Burk
Journal:  J Natl Cancer Inst       Date:  2010-11-23       Impact factor: 13.506

3.  Association between tumor necrosis factor alpha rs1800629 polymorphism and risk of cervical cancer.

Authors:  Lanling Wang; Kunpeng Ma; Zhiyong Wang; Yingying Mou; Li Ma; Yong Guo
Journal:  Int J Clin Exp Med       Date:  2015-02-15

4.  Decreased expression of DNA repair genes (XRCC1, ERCC1, ERCC2, and ERCC4) in squamous intraepithelial lesion and invasive squamous cell carcinoma of the cervix.

Authors:  Deepti Bajpai; Ayan Banerjee; Sujata Pathak; Sunesh K Jain; Neeta Singh
Journal:  Mol Cell Biochem       Date:  2013-02-23       Impact factor: 3.396

5.  The fanconi anemia pathway limits human papillomavirus replication.

Authors:  Elizabeth E Hoskins; Richard J Morreale; Stephen P Werner; Jennifer M Higginbotham; Laimonis A Laimins; Paul F Lambert; Darron R Brown; Maura L Gillison; Gerard J Nuovo; David P Witte; Mi-Ok Kim; Stella M Davies; Parinda A Mehta; Melinda Butsch Kovacic; Kathryn A Wikenheiser-Brokamp; Susanne I Wells
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

6.  Anti-Müllerian hormone deficiency in females with Fanconi anemia.

Authors:  Martha M Sklavos; Neelam Giri; Pamela Stratton; Blanche P Alter; Ligia A Pinto
Journal:  J Clin Endocrinol Metab       Date:  2014-01-17       Impact factor: 5.958

7.  A systemic assessment of the association between tumor necrosis factor alpha 308 G/A polymorphism and risk of cervical cancer.

Authors:  Hua-Lian Zhang; Yi-Jie Zhang
Journal:  Tumour Biol       Date:  2013-03-15

8.  XRCC2 R188H (rs3218536), XRCC3 T241M (rs861539) and R243H (rs77381814) single nucleotide polymorphisms in cervical cancer risk.

Authors:  Luis Orlando Pérez; Andrea Crivaro; Gisela Barbisan; Lucia Poleri; Carlos Daniel Golijow
Journal:  Pathol Oncol Res       Date:  2013-03-29       Impact factor: 3.201

9.  Single nucleotide polymorphisms in DNA repair genes and risk of cervical cancer: A case-control study.

Authors:  Lihua Zhang; Zhenchao Ruan; Qingya Hong; Xiangzhen Gong; Zhengguang Hu; Yan Huang; Aidi Xu
Journal:  Oncol Lett       Date:  2011-10-26       Impact factor: 2.967

10.  Common genetic variants and risk for HPV persistence and progression to cervical cancer.

Authors:  Sophia S Wang; Paula Gonzalez; Kai Yu; Carolina Porras; Qizhai Li; Mahboobeh Safaeian; Ana Cecilia Rodriguez; Mark E Sherman; Concepcion Bratti; Mark Schiffman; Sholom Wacholder; Robert D Burk; Rolando Herrero; Stephen J Chanock; Allan Hildesheim
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.